Margherita Serra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Margherita Serra has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
Alice Pellegrini
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 shared publicationsMarco Bernini
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 shared publicationsMarica Melina
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 shared publications- Mario Taffurelli
UOC di Chirurgia Generale e Della Mammella Policlinico di Sant'Orsola, Università di Bologna, Bologna, Italy
2 shared publications Simone Zanotti
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
2 shared publicationsA. Quattrini Li
Centro Senologico Azienda Ospedaliera Universitaria Pisana Ospedale Santa Chiara, Pisa, Italy
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Bilateral risk reducing mastectomy uptake trends in healthy BRCA1/2 mutation carriers of an European City, the brachoice study
This study evaluates the uptake of bilateral risk-reducing mastectomy (BRRM) among unaffected BRCA1/2 mutation carriers in the metropolitan area of Bologna, Italy, between 2012 and 2024. Pathogenic BRCA variants, which confer a markedly increased lifetime risk of breast cancer, are managed through preventive strategies such as BRRM, which can reduce risk by more than 90%.Among 178 women (89 BRCA1 and 89 BRCA2 carriers), 22.5% elected to undergo BRRM, with a significantly higher uptake among BRCA1 carriers (33.7%) compared with BRCA2 carriers (11.2%). Most procedures were performed more than two years after genetic testing, and the most common age at surgery was 41-45 years.Furthermore, the results demonstrate a progressive increase over time in both genetic testing and BRRM uptake, in line with international trends. However, the observed rates remain lower than those reported in Northern Europe. Despite limitations related to cohort size and data completeness, this study provides updated evidence on decision-making regarding BRRM among Italian women at hereditary risk of breast cancer.
- 28 May 2026
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 24 (1)
Open AccessBilateral risk reducing mastectomy uptake trends in healthy BRCA1/2 mutation carriers of an European City, the brachoice study
This study evaluates the uptake of bilateral risk-reducing mastectomy (BRRM) among unaffected BRCA1/2 mutation carriers in the metropolitan area of Bologna, Italy, between 2012 and 2024. Pathogenic BRCA variants, which confer a markedly increased lifetime risk of breast cancer, are managed through preventive strategies such as BRRM, which can reduce risk by more than 90%.Among 178 women (89 BRCA1 and 89 BRCA2 carriers), 22.5% elected to undergo BRRM, with a significantly higher uptake among BRCA1 carriers (33.7%) compared with BRCA2 carriers (11.2%). Most procedures were performed more than two years after genetic testing, and the most common age at surgery was 41-45 years.Furthermore, the results demonstrate a progressive increase over time in both genetic testing and BRRM uptake, in line with international trends. However, the observed rates remain lower than those reported in Northern Europe. Despite limitations related to cohort size and data completeness, this study provides updated evidence on decision-making regarding BRRM among Italian women at hereditary risk of breast cancer.
- Open Access
- 25 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4083
Breast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis
Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.
- 25 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4083
Open AccessBreast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis
Background/Objectives: Breast cancer is the most common malignancy in young women, many of whom face fertility impairment due to gonadotoxic treatments and prolonged endocrine therapy. Ovarian tissue cryopreservation (OTC) has emerged as an alternative fertility preservation (FP) strategy, particularly when controlled ovarian stimulation is not feasible. This study aimed to evaluate the role of OTC in breast cancer patients, with the aim of clarifying its current clinical role and future perspectives within fertility preservation counselling for this population. Methods: A structured SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis was conducted based on the current literature, addressing clinical efficacy, safety, and applicability of OTC in breast cancer patients. Results: Key strengths of OTC include the absence of delay in cancer treatment and the potential to restore both endocrine and reproductive function. However, limitations include the need for surgery, the theoretical risk of reintroducing malignant cells, and variable, less predictable reproductive outcomes compared with gamete-based strategies. Opportunities lie in advances in cryopreservation, transplantation techniques, and integration with in vitro maturation. Major threats include limited data in breast cancer-specific populations, challenges in BRCA mutation carriers, and low utilization rates affecting cost-effectiveness and healthcare sustainability. Conclusions: OTC represents a valuable complementary FP option for selected breast cancer patients, particularly in urgent settings. Despite promising outcomes, its use should remain individualized within multidisciplinary counseling, considering patient-specific oncological and reproductive factors, while further research is needed to clarify long-term safety and efficacy.
- Open Access
- 3 November 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (1-2) , 109-117
Selective Pectoralis Muscle Denervation Reduces Capsular Contracture in Sub‐Pectoral Breast Reconstruction. Long‐Term Retrospective Case‐ Control Study
Background: Implant‐based breast reconstruction (IBBR) is the most common method of breast reconstruction globally. Although the traditional approach places implants in a retropectoral position, pre‐pectoral reconstruction has recently gained popularity due to its improved aesthetic outcomes and lower capsular contracture (CC) rates. However, not all patients are ideal candidates for prepectoral IBBR, making the retropectoral technique still a valuable option. Capsular contracture is a common complication of IBBR, causing discomfort, pain, poor cosmetic results, and often necessitating revision surgery, particularly in retropectoral cases. Selective denervation of the pectoralis major muscle (PMM) in retropectoral IBBR is a novel technique to reduce these complications. Material and Methods: We selected a group of denervated retro‐pec IBBR patients and compared them to non‐denervated patients. In a previous study, we analyzed the subjective opinions on the reconstruction outcomes using the BREAST‐Q postoperative questionnaire. At the same time, we compared retrospectivally the same groups, with a minimum 24‐month follow‐up, from an objective perspective, evaluating CC rates by Baker scale and possible implant malrotation through outpatient clinic visits performed by three independent breast cancer professionals. Results: The overall mean follow‐up was 3.33 (±0.47) years, and the CC rate was significantly lower in Group 1, even adjusting for the propensity score. Conclusions: PMM selective denervation has gained statistical appreciation by women and significantly reduced the CC rate from an objective evaluation in the setting of retro‐pectoral IBBR in our series.
- 3 November 2025
- Published by Wiley in Anz Journal of Surgery
- Vol. 96 (1-2) , 109-117
Open AccessSelective Pectoralis Muscle Denervation Reduces Capsular Contracture in Sub‐Pectoral Breast Reconstruction. Long‐Term Retrospective Case‐ Control Study
Background: Implant‐based breast reconstruction (IBBR) is the most common method of breast reconstruction globally. Although the traditional approach places implants in a retropectoral position, pre‐pectoral reconstruction has recently gained popularity due to its improved aesthetic outcomes and lower capsular contracture (CC) rates. However, not all patients are ideal candidates for prepectoral IBBR, making the retropectoral technique still a valuable option. Capsular contracture is a common complication of IBBR, causing discomfort, pain, poor cosmetic results, and often necessitating revision surgery, particularly in retropectoral cases. Selective denervation of the pectoralis major muscle (PMM) in retropectoral IBBR is a novel technique to reduce these complications. Material and Methods: We selected a group of denervated retro‐pec IBBR patients and compared them to non‐denervated patients. In a previous study, we analyzed the subjective opinions on the reconstruction outcomes using the BREAST‐Q postoperative questionnaire. At the same time, we compared retrospectivally the same groups, with a minimum 24‐month follow‐up, from an objective perspective, evaluating CC rates by Baker scale and possible implant malrotation through outpatient clinic visits performed by three independent breast cancer professionals. Results: The overall mean follow‐up was 3.33 (±0.47) years, and the CC rate was significantly lower in Group 1, even adjusting for the propensity score. Conclusions: PMM selective denervation has gained statistical appreciation by women and significantly reduced the CC rate from an objective evaluation in the setting of retro‐pectoral IBBR in our series.
- Open Access
- 23 November 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (5) , 384-391
Prognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors
Purpose: The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods: Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results: A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer
- 23 November 2023
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 29 (5) , 384-391
Open AccessPrognostic Role of p53 Immunohistochemical Status in Invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors
Purpose: The aim of this study was to evaluate the prognostic role of p53 immunohistochemical (IHC) expression in a large cohort of patients with hormone receptors (HR)-positive/Her2-negative primary invasive breast cancer. Methods: Retrospective review of consecutive cases treated at our Breast Unit between 2003 and 2013. Patients were divided into 3 subgroups based on p53 IHC expression: null (0%), low (0.1%-49%), and high (≥50%) p53 expression. Results: A total of 1387 patients were included in the study with a median follow-up of 86 months. After adjusting for age, size, node status, lymphovascular invasion, progesterone, and Ki67 expression, only null p53 immunophenotype was associated with worse disease-free survival (DFS) (OR 1.74, 95% IC, 1.11-2.71, P = .015) and distant recurrence-free survival (DRFS) (OR 1.73, 95% IC, 1.04-2.90, P = .036). Null p53 impacted significantly DFS and DRFS also in patients with early breast cancer. Conclusions: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1861-1866
Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers
- 1 October 2020
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 46 (10) , 1861-1866
Aesthetic results following breast cancer surgery: A prospective study on 6515 cases from ten Italian Senonetwork breast centers
- Open Access
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Locoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Open AccessLocoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy